Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,424.85 162.29 1.00%
S&P 500 1,862.31 19.33 1.05%
NASDAQ 4,086.22 52.06 1.29%
Ticker Volume Price Price Delta
STOXX 50 3,130.97 -8.29 -0.26%
FTSE 100 6,588.12 3.95 0.06%
DAX 9,309.68 -8.14 -0.09%
Ticker Volume Price Price Delta
NIKKEI 14,417.53 -0.15 -0.00%
TOPIX 1,166.59 0.04 0.00%
HANG SENG 22,760.24 64.23 0.28%

Durata Therapeutics to Present Two Dalbavancin Posters at the 23rd Annual ECCMID Meeting



Durata Therapeutics to Present Two Dalbavancin Posters at the 23rd Annual
ECCMID Meeting

CHICAGO, April 24, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc.
(Nasdaq:DRTX) today announced that data from two clinical trials of the
company's lead product candidate, dalbavancin, will be presented in two
posters at the 23^rd Annual European Congress of Clinical Microbiology and
Infectious Diseases (ECCMID), which takes place in Berlin, Germany from April
27-30, 2013.

The following posters will be presented:

Saturday, April 27, 2013
15:30 - 16:30
Title: A study to evaluate the safety, tolerability, and pharmacokinetics of
multiple weekly doses of intravenous dalbavancin in healthy subjects
Authors: M. Dunne, C. Sprenger, S. Moriarty (Branford, US)
Poster #: P910
 
Sunday, April 28, 2013 
13:30 - 14:30
Title: Dalbavancin activity in the USA: reported from the SENTRY Programme
(2012)
Authors: R.N. Jones, R.K. Flamm, H.S. Sader, B.P. Goldstein, M. Dunne (North
Liberty, Morristown, US)
Poster #: P1646

Copies of these posters will be available on Durata's website following the
ECCMID Meeting: www.duratatherapeutics.com.  

About Dalbavancin

Dalbavancin is an intravenous antibiotic product candidate under investigation
for once-weekly dosing, which we believe may facilitate the treatment of
patients with ABSSSI in both the in-patient and out-patient settings,
potentially reducing the length of a patient's hospital stay or avoiding
hospital admission altogether, with an impact on the overall cost of care for
these patients. 

About Durata Therapeutics

Durata Therapeutics is a pharmaceutical company focused on the development and
commercialization of novel therapeutics for patients with infectious diseases
and acute illnesses. Durata has completed two global Phase 3 clinical trials
with its lead product candidate, dalbavancin, under investigation for the
treatment of patients with acute bacterial skin and skin structure infections,
or ABSSSI.

Forward-looking Statements

Statements contained in this press release contain forward-looking statements
that involve substantial risks and uncertainties. All statements, other than
statements of historical facts, contained in this press release, including
statements regarding our strategy, future operations, future financial
position, future revenues, projected costs, prospects, plans and objectives of
management, are forward-looking statements. The words "anticipate," "believe,"
"estimate," "expect," "intend," "may," "plan," "predict," "project," "target,"
"potential," "will," "would," "could," "should," "continue," and similar
expressions are intended to identify forward-looking statements, although not
all forward-looking statements contain these identifying words.

CONTACT: Investor Relations and Public Affairs Contact
         Allison Wey
         Durata Therapeutics
         Vice President, Investor Relations and Public Affairs
         (312) 219-7017
         awey@duratatherapeutics.com
        
         Media Relations Contact
         Jed Weiner
         White Oak Communications, Inc.
         (847) 392-4186
         jed.weiner@comcast.net

Durata Therapeutics, Inc. Logo
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement